Actinium Pharmaceuticals, Inc.
ATNM- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001388320
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $5.18M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −6 vs. previous quarter
- 47
- 13F valueReported value at the end of Q2 2026
- $5.18M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ATNM, Q2 2026
No superinvestor reported holding ATNM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Actinium Pharmaceuticals, Inc. insiders from Form 4, newest first.
No open-market purchases or sales by Actinium Pharmaceuticals, Inc. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Actinium Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,238,302 | $1.21M | 0.00% | −17,214−1.4% | Reduced |
| Compass Financial Management LLC | 600,230 | $588.2K | 0.07% | +600,230 | New |
| Millennium Management LLC | 514,580 | $504.3K | 0.00% | −50,020−8.9% | Reduced |
| Acadian Asset Management LLC | 496,288 | $485.0K | 0.00% | −104,531−17.4% | Reduced |
| BlackRock, Inc. | 395,896 | $388.0K | 0.00% | +24,686+6.7% | Added |
| Renaissance Technologies LLC | 380,491 | $372.9K | 0.00% | −91,109−19.3% | Reduced |
| Geode Capital Management, LLC | 324,945 | $318.6K | 0.00% | −11,128−3.3% | Reduced |
| Two Sigma Investments, LP | 259,179 | $254.0K | 0.00% | −77,989−23.1% | Reduced |
| Gagnon Securities LLC | 182,142 | $178.5K | 0.03% | −19,158−9.5% | Reduced |
| Vanguard Fiduciary Trust Co | 161,526 | $158.3K | 0.00% | +1,261+0.8% | Added |